Renal Cell Carcinoma Microenvironment Discovery Project

Titre officiel

Molecular Dissection of the Renal Cell Carcinoma Tumour Microenvironment for the Discovery of Novel Therapeutic Targets

Sommaire:

Cette étude permettra d’obtenir dans différentes régions des échantillons tumoraux à partir de pièces de néphrectomie et de les soumettre à des évaluations génomiques, pathologiques et radiologiques. L’objectif est de mieux comprendre les mécanismes moléculaires à l’origine de la coordination de diverses cellules du microenvironnement tumoral dans la progression tumorale et la résistance au traitement. Notre but ultime est de tirer parti de ces données pour mettre en évidence de nouvelles cibles thérapeutiques et de nouveaux biomarqueurs en vue d’améliorer la prise en charge clinique de cette maladie.

Description de l'essai

Primary Outcome:

• Molecular profiling of various cell populations within tumour by using single cell RNAseq.
• Determination of the radiological and pathological features associated with the derived tumour microenvironment molecular data

This study is an observational prospective trial where renal cell carcinoma samples are isolated from nephrectomy specimens in a multi-regional manner and subjected to an integrated genomic, pathological and radiological assessment to provide a detailed morphological and molecular view of the RCC microenvironment. The major genomics technologies used to examine tumour specimens include single cell RNA sequencing including nuclear (NUCseq) and epitope sequencing (CITEseq). Additionally, bulk RNA/DNA sequencing, targeted mutational profiling, and imaging mass cytometry will be performed. These technologies will determine mutational and gene/protein expression profiles of various heterogeneous cell populations within the tumour microenvironment, including cancer, immune, and supporting cells. This will allow identification of mutations and abnormal expression patterns within individual cells, that will be used to infer targetable vulnerabilities and biomarker signatures. In addition, ex vivo tumour magnetic resonance imaging (MRI) and digital pathology will be performed on a subset of cases to facilitate correlative radio -genomic and -pathological assessment.

Voir cet essai sur ClinicalTrials.gov